Profil
Mads Hald Andersen is the founder of RhoVac AB (founded in 2015) and IO Biotech, Inc. (founded in 2014).
Dr. Andersen is also the founder of IO Biotech ApS.
Dr. Andersen's former job was as an Administrative Director at Survac ApS.
Dr. Andersen's education includes a doctorate degree from the University of Copenhagen.
Aktive Positionen von Mads Hald Andersen
Unternehmen | Position | Beginn |
---|---|---|
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Gründer | - |
Ehemalige bekannte Positionen von Mads Hald Andersen
Unternehmen | Position | Ende |
---|---|---|
CHOSA ONCOLOGY AB | Gründer | - |
IO BIOTECH, INC. | Gründer | - |
Survac ApS
Survac ApS Pharmaceuticals: OtherHealth Technology Survac ApS specializes in the development of peptide based therapeutic cancer vaccines. It offers the vaccine candidates for licensing and collaboration agreements. The company's vaccine is being examined in clinical phase I & II trials. Survac was founded in 2003 and is located in Hellerup, Denmark | Verwaltungsdirektor | - |
Ausbildung von Mads Hald Andersen
University of Copenhagen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
IO BIOTECH, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Survac ApS
Survac ApS Pharmaceuticals: OtherHealth Technology Survac ApS specializes in the development of peptide based therapeutic cancer vaccines. It offers the vaccine candidates for licensing and collaboration agreements. The company's vaccine is being examined in clinical phase I & II trials. Survac was founded in 2003 and is located in Hellerup, Denmark | Health Technology |
RhoVac AB
RhoVac AB BiotechnologyHealth Technology RhoVac AB opertaes as biotechnology company that engages in the research and development of immunotherapy. The firm develops therapeutic cancer vaccines. Its main focus is the development of a drug with the potential to prevent or limit the metastasis of metastatic cancers. The company was founded by Bo Anders Ljungqvist, Per Thor Straten, and Mads Hald Andersen in November 2015 and is headquartered in Lund, Sweden. | Health Technology |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Health Technology |